ATOPIC DERMATITIS (AD)

This study looks at the long-term safety and effectiveness of a drug called CM512 for people with atopic dermatitis (eczema). It is for patients who already finished a previous CM512 study. The main goal is to track any side effects over time. About 246 adults will take part.

This study looks at whether using CeraVe emollient can keep the skin barrier hydrated and prevent eczema from coming back after a short course of steroid cream. About 98 adults with mild-to-moderate atopic dermatitis will first use a steroid to clear their rash, then be split int…

This study tests whether a partially hydrolyzed formula with added synbiotics can prevent atopic dermatitis (eczema) in 400 infants at high risk for allergies. The main goal is to see if the formula improves skin barrier function by 3 months of age. Researchers will also track ho…

This early-stage study tests a new drug called ATTO-3712 in 72 healthy adults and people with atopic dermatitis (eczema). The main goal is to see if the drug is safe and how long it stays in the body. Participants receive either the drug or a placebo and are monitored with clinic…

This early-stage study tests an over-the-counter drug for atopic dermatitis (eczema) in 36 adults with active flare-ups. Researchers will check how the treatment affects skin bacteria, hydration, and barrier function. The goal is to see if the product can ease symptoms and improv…

This early-stage study tests the safety of an experimental oral drug, LPX-TI641, in 48 adults with atopic dermatitis (eczema) or psoriasis. Participants take the drug or a placebo daily for 28 days. The main goal is to check for side effects and how the drug moves through the bod…

This study tests whether a daily pill called ENV-294 can safely reduce eczema severity and itch in adults with moderate-to-severe atopic dermatitis. About 60 participants will take either the drug or a placebo for 12 weeks, with regular clinic visits and symptom diaries. The goal…

This study tests whether a cream made with glycomacropeptide (a milk protein) can reduce itching, redness, and skin bacteria in children aged 2 to 12 with mild eczema. Twenty kids will apply either the special cream or a plain moisturizer twice a day for four weeks. Researchers w…

This early-stage study tests whether a new drug called ZL-1503 is safe for people with moderate to severe atopic dermatitis (eczema). It involves 84 participants, including healthy volunteers and those with eczema, who receive either the drug or a placebo. The main goal is to che…

This early-stage study tests a new medicine called ARQ-234 in healthy people and those with moderate to severe eczema (atopic dermatitis). The main goals are to check safety and see if the drug can reduce skin symptoms like redness and itching. About 125 adults will take part, an…

This study tests an experimental drug called BFB759 for adults with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with standard creams. About 225 participants will receive either BFB759 or a placebo for up to 40 weeks. Researchers will track changes in skin r…

This study looks at whether certain self-reactive antibodies (IgE autoantibodies) are present at birth in babies with a family history of eczema, asthma, or hay fever. Researchers will test umbilical cord blood and follow the babies for two years to see if these antibodies are li…

This early-stage study looks at how botulinum toxin changes the way skin cells and nerves interact in people with mild-to-moderate eczema. Researchers will measure eczema severity and analyze skin samples to understand these changes. The goal is to learn more about the disease, n…

This early-stage study tests a new drug called GS101 in healthy volunteers to see how it compares to the approved eczema treatment Dupixent. The goal is to check if GS101 is processed similarly in the body, how safe it is, and whether it triggers an immune response. About 294 hea…

This study is looking at 15 adults with moderate-to-severe eczema (atopic dermatitis) who are starting treatment with tralokinumab. Researchers will use a special, non-invasive microscope called reflectance confocal microscopy to take detailed pictures of the skin's structure. Th…